Predicting Weight Loss Response to Semaglutide or Tirzepatide Using Genetic Markers
Studies whether genetic markers predict weight loss with semaglutide or tirzepatide in adults with obesity.
Plain-language title generated from the registry record
Registry title: Precision Obesity Medicine: Genetic Prediction of Response to GLP-1/GIP Agonists.
Key facts
- Where
- Athens, GreeceSee the site
Where in Greece
- Laiko General Hospital, AthensAthens, GreeceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- National and Kapodistrian University of Athens
- Trial code
- NCT07653412
- Record updated
- 10 July 2026
- Original description
Obesity is a chronic multifactorial disease with a strong genetic component. Although glucagon-like peptide-1 (GLP-1) receptor agonists such as semaglutide and dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonists, such as tirzepatide, are highly effective treatments for obesity, substantial inter-individual variability in weight loss response remains. Genetic factors may contribute to these differences in treatment outcomes.Read full original descriptionShow less
Prediction of Response to GLP-1/GIP Receptor Agonists in Obesity Using Genetic Risk Score and SNP Profiling: A Prospective Cohort Study.
Obesity is a chronic multifactorial disease with a strong genetic component. Although glucagon-like peptide-1 (GLP-1) receptor agonists such as semaglutide and dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonists, such as tirzepatide, are highly effective treatments for obesity, substantial inter-individual variability in weight loss response remains. Genetic factors may contribute to these differences in treatment outcomes.
The aim of this prospective cohort study is to investigate whether a Genetic Risk Score (GRS) and selected obesity-related single nucleotide polymorphisms (SNPs) can predict weight loss response to semaglutide or tirzepatide in adults with obesity. Participants initiating treatment with either medication will undergo clinical, biochemical, and genetic assessment at baseline and will be followed for six months. The study will evaluate the association between genetic markers and treatment response and develop predictive models integrating genetic and clinical variables. The findings may contribute to the development of personalized treatment strategies for obesity.
Inclusion: Age ≥18 years; BMI ≥40 kg/m² or ≥37 kg/m² with comorbidities; Initiation of semaglutide or tirzepatide.
Exclusion: Prior bariatric surgery; Active malignancy; Family history of medullary thyroid carcinoma; Secondary causes of obesity; Chronic pancreatitis.